Searching for New Biomarkers to Assess COVID-19 Patients: A Pilot Study
During the initial diagnosis of urgent medical conditions, which include acute infectious diseases, it is important to assess the severity of the patient’s clinical state as quickly as possible. Unlike individual biochemical or physiological indicators, derived indices make it possible to better cha...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/13/12/1194 |
| _version_ | 1797380097627389952 |
|---|---|
| author | Nikolay V. Goncharov Piotr P. Avdonin Natalia G. Voitenko Polina A. Voronina Polina I. Popova Artemy V. Novozhilov Maria S. Blinova Victoria S. Popkova Daria A. Belinskaia Pavel V. Avdonin |
| author_facet | Nikolay V. Goncharov Piotr P. Avdonin Natalia G. Voitenko Polina A. Voronina Polina I. Popova Artemy V. Novozhilov Maria S. Blinova Victoria S. Popkova Daria A. Belinskaia Pavel V. Avdonin |
| author_sort | Nikolay V. Goncharov |
| collection | DOAJ |
| description | During the initial diagnosis of urgent medical conditions, which include acute infectious diseases, it is important to assess the severity of the patient’s clinical state as quickly as possible. Unlike individual biochemical or physiological indicators, derived indices make it possible to better characterize a complex syndrome as a set of symptoms, and therefore quickly take a set of adequate measures. Recently, we reported on novel diagnostic indices containing butyrylcholinesterase (BChE) activity, which is decreased in COVID-19 patients. Also, in these patients, the secretion of von Willebrand factor (vWF) increases, which leads to thrombosis in the microvascular bed. The objective of this study was the determination of the concentration and activity of vWF in patients with COVID-19, and the search for new diagnostic indices. One of the main objectives was to compare the prognostic values of some individual and newly derived indices. Patients with COVID-19 were retrospectively divided into two groups: survivors (n = 77) and deceased (n = 24). According to clinical symptoms and computed tomography (CT) results, the course of disease was predominantly moderate in severity. The first blood sample (first point) was taken upon admission to the hospital, the second sample (second point)—within 4–6 days after admission. Along with the standard spectrum of biochemical indicators, BChE activity (BChEa or BChEb for acetylthiocholin or butyrylthiocholin, respectively), malondialdehyde (MDA), and vWF analysis (its antigen level, AGFW, and its activity, ActWF) were determined and new diagnostic indices were derived. The pooled sensitivity, specificity, and area under the receiver operating curve (AUC), as well as Likelihood ratio (LR) and Odds ratio (OR) were calculated. The level of vWF antigen in the deceased group was 1.5-fold higher than the level in the group of survivors. Indices that include vWF antigen levels are superior to indices using vWF activity. It was found that the index [Urea] × [AGWF] × 1000/(BChEb × [ALB]) had the best discriminatory power to predict COVID-19 mortality (AUC = 0.91 [0.83, 1.00], <i>p</i> < 0.0001; OR = 72.0 [7.5, 689], <i>p</i> = 0.0002). In addition, [Urea] × 1000/(BChEb × [ALB]) was a good predictor of mortality (AUC = 0.95 [0.89, 1.00], <i>p</i> < 0.0001; OR = 31.5 [3.4, 293], <i>p</i> = 0.0024). The index [Urea] × [AGWF] × 1000/(BChEb × [ALB]) was the best predictor of mortality associated with COVID-19 infection, followed by [Urea] × 1000/(BChEb × [ALB]). After validation in a subsequent cohort, these two indices could be recommended for diagnostic laboratories. |
| first_indexed | 2024-03-08T20:33:16Z |
| format | Article |
| id | doaj.art-f73a727ab9d1487d803d8df98c2aba55 |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-08T20:33:16Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-f73a727ab9d1487d803d8df98c2aba552023-12-22T14:24:28ZengMDPI AGMetabolites2218-19892023-12-011312119410.3390/metabo13121194Searching for New Biomarkers to Assess COVID-19 Patients: A Pilot StudyNikolay V. Goncharov0Piotr P. Avdonin1Natalia G. Voitenko2Polina A. Voronina3Polina I. Popova4Artemy V. Novozhilov5Maria S. Blinova6Victoria S. Popkova7Daria A. Belinskaia8Pavel V. Avdonin9Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg 194223, RussiaKoltsov Institute of Developmental Biology, Russian Academy of Sciences, Moscow 119334, RussiaSechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg 194223, RussiaSechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg 194223, RussiaCity Polyclinic No.112, Saint Petersburg 195427, RussiaSechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg 194223, RussiaKoltsov Institute of Developmental Biology, Russian Academy of Sciences, Moscow 119334, RussiaKoltsov Institute of Developmental Biology, Russian Academy of Sciences, Moscow 119334, RussiaSechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint Petersburg 194223, RussiaKoltsov Institute of Developmental Biology, Russian Academy of Sciences, Moscow 119334, RussiaDuring the initial diagnosis of urgent medical conditions, which include acute infectious diseases, it is important to assess the severity of the patient’s clinical state as quickly as possible. Unlike individual biochemical or physiological indicators, derived indices make it possible to better characterize a complex syndrome as a set of symptoms, and therefore quickly take a set of adequate measures. Recently, we reported on novel diagnostic indices containing butyrylcholinesterase (BChE) activity, which is decreased in COVID-19 patients. Also, in these patients, the secretion of von Willebrand factor (vWF) increases, which leads to thrombosis in the microvascular bed. The objective of this study was the determination of the concentration and activity of vWF in patients with COVID-19, and the search for new diagnostic indices. One of the main objectives was to compare the prognostic values of some individual and newly derived indices. Patients with COVID-19 were retrospectively divided into two groups: survivors (n = 77) and deceased (n = 24). According to clinical symptoms and computed tomography (CT) results, the course of disease was predominantly moderate in severity. The first blood sample (first point) was taken upon admission to the hospital, the second sample (second point)—within 4–6 days after admission. Along with the standard spectrum of biochemical indicators, BChE activity (BChEa or BChEb for acetylthiocholin or butyrylthiocholin, respectively), malondialdehyde (MDA), and vWF analysis (its antigen level, AGFW, and its activity, ActWF) were determined and new diagnostic indices were derived. The pooled sensitivity, specificity, and area under the receiver operating curve (AUC), as well as Likelihood ratio (LR) and Odds ratio (OR) were calculated. The level of vWF antigen in the deceased group was 1.5-fold higher than the level in the group of survivors. Indices that include vWF antigen levels are superior to indices using vWF activity. It was found that the index [Urea] × [AGWF] × 1000/(BChEb × [ALB]) had the best discriminatory power to predict COVID-19 mortality (AUC = 0.91 [0.83, 1.00], <i>p</i> < 0.0001; OR = 72.0 [7.5, 689], <i>p</i> = 0.0002). In addition, [Urea] × 1000/(BChEb × [ALB]) was a good predictor of mortality (AUC = 0.95 [0.89, 1.00], <i>p</i> < 0.0001; OR = 31.5 [3.4, 293], <i>p</i> = 0.0024). The index [Urea] × [AGWF] × 1000/(BChEb × [ALB]) was the best predictor of mortality associated with COVID-19 infection, followed by [Urea] × 1000/(BChEb × [ALB]). After validation in a subsequent cohort, these two indices could be recommended for diagnostic laboratories.https://www.mdpi.com/2218-1989/13/12/1194von Willebrand factorCOVID-19endothelial cellsdiagnosticsbiomarkeralbumin |
| spellingShingle | Nikolay V. Goncharov Piotr P. Avdonin Natalia G. Voitenko Polina A. Voronina Polina I. Popova Artemy V. Novozhilov Maria S. Blinova Victoria S. Popkova Daria A. Belinskaia Pavel V. Avdonin Searching for New Biomarkers to Assess COVID-19 Patients: A Pilot Study Metabolites von Willebrand factor COVID-19 endothelial cells diagnostics biomarker albumin |
| title | Searching for New Biomarkers to Assess COVID-19 Patients: A Pilot Study |
| title_full | Searching for New Biomarkers to Assess COVID-19 Patients: A Pilot Study |
| title_fullStr | Searching for New Biomarkers to Assess COVID-19 Patients: A Pilot Study |
| title_full_unstemmed | Searching for New Biomarkers to Assess COVID-19 Patients: A Pilot Study |
| title_short | Searching for New Biomarkers to Assess COVID-19 Patients: A Pilot Study |
| title_sort | searching for new biomarkers to assess covid 19 patients a pilot study |
| topic | von Willebrand factor COVID-19 endothelial cells diagnostics biomarker albumin |
| url | https://www.mdpi.com/2218-1989/13/12/1194 |
| work_keys_str_mv | AT nikolayvgoncharov searchingfornewbiomarkerstoassesscovid19patientsapilotstudy AT piotrpavdonin searchingfornewbiomarkerstoassesscovid19patientsapilotstudy AT nataliagvoitenko searchingfornewbiomarkerstoassesscovid19patientsapilotstudy AT polinaavoronina searchingfornewbiomarkerstoassesscovid19patientsapilotstudy AT polinaipopova searchingfornewbiomarkerstoassesscovid19patientsapilotstudy AT artemyvnovozhilov searchingfornewbiomarkerstoassesscovid19patientsapilotstudy AT mariasblinova searchingfornewbiomarkerstoassesscovid19patientsapilotstudy AT victoriaspopkova searchingfornewbiomarkerstoassesscovid19patientsapilotstudy AT dariaabelinskaia searchingfornewbiomarkerstoassesscovid19patientsapilotstudy AT pavelvavdonin searchingfornewbiomarkerstoassesscovid19patientsapilotstudy |